Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00028707
DRKS00028707
Recruiting
Not Applicable

Evaluation of Transplant-reactive T cells for the Prediction or Diagnosis of Transplant Rejection in Kidney Transplant Recipients (TreaT-Assay) - TreaT-Assay

Charité Campus Virchow-Klinikum0 sites185 target enrollmentApril 27, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsT86.10T86.11T86.12T86.19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
T86.10
Sponsor
Charité Campus Virchow-Klinikum
Enrollment
185
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 27, 2022
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Charité Campus Virchow-Klinikum

Eligibility Criteria

Inclusion Criteria

  • •Condition after kidney transplant or non\-kidney transplant control
  • •\- Deterioration of transplant function and indication for renal transplant biopsy
  • •\- Signed informed consent form
  • •\- Age \>18 years
  • •\- Existing health insurance

Exclusion Criteria

  • •\- Age under 18 years
  • •\- Lack of capacity to give consent
  • •\- Lack of written informed consent
  • •\- viral infections such as hepatitis B, hepatitis C or/and HIV

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A pilot study to characterize T cell responses in young children after influenza infectioinfluenza10047438
NL-OMON33577niversitair Medisch Centrum Utrecht125
Completed
Not Applicable
An initial study to determine the T lymphocyte response in seriously ill COVID-19 patients: An observational study in Pune, IndiaHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B342- Coronavirus infection, unspecified
CTRI/2021/03/032028Dr D Y Patil Vidyapeeth Pune137
Not yet recruiting
Not Applicable
Adoptive Transfer of T cell Receptor-engineered T cells to treat hepAtocellular Carcinoma recurrence after liver Transplantation: a preclinical feasibility studyLiver CancerPrimary Liver Cell Carcinoma100196541000381610019815
NL-OMON47991Erasmus MC, Universitair Medisch Centrum Rotterdam35
Recruiting
Not Applicable
Investigation of drug specific cytotoxic T cell in severe cutaneous adverse drug reactio
JPRN-UMIN000009708Yokohama City University Graduate School of Medicine10
Recruiting
Phase 1
Immune cell therapy for pediatric patients with brain tumor.Malignant brain tumor
JPRN-jRCTc030200051Kondo Akihide3